PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
about
Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationEmerging therapeutic agents for lung cancerAdjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationMechanisms of action of therapeutic antibodies for cancerEngineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imagingCombination immunotherapy: a road map.Past, present and future targets for immunotherapy in ovarian cancerCombined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.Programmed death-1 (PD-1) rs2227981 C > T polymorphism is associated with cancer susceptibility: a meta-analysis.A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory ResponsesEnhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine.Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.Checkpoint inhibitors in immunotherapy of ovarian cancer.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.Breast cancer and immunology: biomarker and therapeutic developments.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.Immuno-oncology combinations: raising the tail of the survival curve.Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.Immune checkpoint inhibitors in cancer therapy.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
P2860
Q28066199-D57C15FC-A388-4067-8615-CCDA526C7B29Q28068378-AE22A721-9993-4068-A555-8099BDAE632AQ28070165-4C6B97A1-54F9-4BE0-A6FE-65DD0053759DQ28074536-47ED4016-3019-41E0-97F6-0FE137A99113Q28385366-5E63C0E5-865F-4E79-A33A-9CAFD7D6EF48Q34502985-E8B9F5EA-FC64-4E46-884B-930470DC3838Q34552128-405920AF-A4E9-4A93-A3B3-C1060051B7D2Q35034010-A923A07E-A956-4366-B4CC-CD61AFA76684Q35896426-2AF0DBAA-5954-4478-9E9D-649E16A7212EQ36024656-6A43DC0C-BA3E-46E9-8115-F3DA2CA3D443Q36360125-2D1BD24C-E3FB-4B24-AADF-583549D8D8EBQ36413093-BCE9FF20-C862-457D-A988-AFB8F7C3E236Q36511487-307135D3-1F8E-4AA1-B0DC-3F204B5FF13DQ36535147-66770986-B659-4862-9B8F-40AB715C794BQ36940326-A2E1E150-5349-40CB-A152-0BDBE4920F95Q37114367-DDF020C5-11EF-407A-91A0-26D3B81AB4EFQ37286424-EA0C17D8-6F83-496E-AE62-C08B14E42E94Q37664203-2AEA8626-0CE6-45BC-AAD0-E10B88C9493CQ37709902-2E158F04-4B26-4C00-B65A-2B6C8BBD7798Q38269568-E80FDCDE-2DE1-4217-93E6-4E5406D53F1AQ38374889-D9ADA64F-D7A6-4135-AF25-9F8A3E2594B5Q38562062-EC8B37FF-C6F2-437E-A2D7-923E2250C83BQ38584383-262270BE-EE56-4A3E-8BE7-6C872AB98F3AQ38621228-30944494-2945-4B55-AB94-2664D0E0D9B4Q38636430-594B76AE-7CC8-404D-BD75-F77BE865DB71Q38666253-18C298BF-BE1F-44EC-82BD-D20EC3A0B2C6Q38770458-DE586799-3098-4884-BEDC-47BC02FC3670Q38770814-FAD35DBF-934F-4A39-9A67-FBF98AE7A60FQ38806038-CBFF6977-A1B7-4D0E-AF35-1CEF8361F0A4Q38865403-FEF86252-52F2-453A-B919-8857CA739706Q39190801-D39403A7-E61C-44E4-8307-E042E6BF1111Q39402079-619B1018-8F6E-4EE8-BF12-CDE547F590AAQ39559063-F4A27547-7769-4C9E-B00E-4B5D42547ECEQ41939949-FF84FEA2-8454-44FD-B7F8-0BCA4DA34391Q42421273-9C5A197A-3151-4EA8-91FC-975FAA2FDB2DQ42680229-6915B0C8-62FE-4D1B-8842-27BB46CB8621Q45871487-91EF0EC0-F3ED-44E2-A441-2EF5AE1B276CQ46047154-C44A9B7D-2F9D-448C-BB7B-B65FBA745448Q47222860-A6596412-7E3D-4A1F-A98B-B3BF9DFAC570Q47820348-57D0826E-FB99-47D3-84D1-7EC9D8D10DC7
P2860
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@ast
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@en
type
label
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@ast
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@en
prefLabel
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@ast
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@en
P2093
P2860
P1433
P1476
PD-1 blockade and OX40 trigger ...... urine model of ovarian cancer.
@en
P2093
Dali Cheng
Shulan Zhang
Zhijun Xia
Zhiqiang Guo
P2860
P304
P356
10.1371/JOURNAL.PONE.0089350
P407
P577
2014-02-27T00:00:00Z